Stocks of Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) traded higher last session on Wall Street, up 10.39% to $5.95.
According to the data, Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) has 12 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $30.00 and a low of $6.00, we find $11.00. Given the previous closing price of $5.39, this indicates a potential upside of 104.08 percent. BCRX stock price is now 3.88% away from the 50-day moving average and -17.81% away from the 200-day moving average. The market capitalization of the company currently stands at $1.22B.
A total of 2 analysts have issued a hold rating and 10 have given it a buy rating. Brokers who have rated the stock have averaged $14.09 as their price target over the next twelve months.
In other news, SANDERS MACHELLE, Director sold 4,000 shares of the company’s stock on Jun 15. The stock was sold for $31,920 at an average price of $7.98. Upon completion of the transaction, the Director now directly owns 25,611 shares in the company, valued at $0.15 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 14, Director Hutson Nancy J sold 12,866 shares of the business’s stock. A total of $103,443 was realized by selling the stock at an average price of $8.04. This leaves the insider owning 81,818 shares of the company worth $0.49 million. Insiders disposed of 192,511 shares of company stock worth roughly $1.15 million over the past 1 year. A total of 2.99% of the company’s stock is owned by insiders.
Tuesday’s opening bell rang with an opening price of $5.38 for Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX). During the past 12 months, Biocryst Pharmaceuticals Inc. has had a low of $4.82 and a high of $12.07. The fifty day moving average price for BCRX is $5.73 and a two-hundred day moving average price translates $7.24 for the stock.
The latest earnings results from Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.19, beating analysts’ expectations of -$0.23 by 0.04. This compares to -$0.23 EPS in the same period last year. The company reported revenue of $86.74 million for the quarter, compared to $75.83 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.39 percent. For the current quarter, analysts expect BCRX to generate $89.59M in revenue.
Biocryst Pharmaceuticals Inc.(BCRX) Company Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
